Korro Bio Inc. (KRRO)
| Market Cap | 35.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.32M |
| Shares Out | 738.45K |
| EPS (ttm) | -83.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,106 |
| Open | 48.71 |
| Previous Close | 49.16 |
| Day's Range | 47.93 - 52.24 |
| 52-Week Range | 0.18 - 71.67 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 116.67 (+143.42%) |
| Earnings Date | Nov 2, 2023 |
About KRRO
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price forecast is $116.67, which is an increase of 143.42% from the latest price.
News
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly ...
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
Biotech veteran brings more than two decades of life science experience to Korro's Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical...
UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
CAMBRIDGE, Mass. and LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new...
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
CAMBRIDGE, Mass. and LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new...
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Frequency Therap...
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company a...
FREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Frequency Therapeutics, Inc. (NASDAQ: FREQ) and Korro Bio, Inc. is fair to Frequency sh...
Korro Bio and Frequency Therapeutics Announce Merger Agreement
CAMBRIDGE & LEXINGTON, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. (Nas...
Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore fu...
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore fu...
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore fu...
Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth
Detailed research on the small animal imaging in vivo market is just released by SkyQuest. Using cutting-edge analytical methods and methodology, this study delivers a thorough industry analysis and a...
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore fu...
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potent...
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potent...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Frequency Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Nov. 29, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim...
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potent...
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
LEXINGTON, Mass.
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
LEXINGTON, Mass.
Frequency Therapeutics to Participate in September Investor and Medical Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potentia...
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potentia...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Frequency Therapeutics, Inc.
Wilmington, Delaware--(Newsfile Corp. - May 18, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Frequency Therapeutics, Inc. (NasdaqGS: FREQ) on beh...
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenera...
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenera...
Frequency Therapeutics to Participate in B. Riley Securities' Neuro & Ophthalmology Investor Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenera...